Back to Search
Start Over
Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer
- Source :
- Journal of Clinical Oncology, 37(1), 33, Journal of Clinical Oncology, 37(1), 33-43. American Society of Clinical Oncology, Ogura, A, Konishi, T, Cunningham, C, Garcia-Aguilar, J, Iversen, H, Toda, S, Lee, I K, Lee, H X, Uehara, K, Lee, P, Putter, H, van de Velde, C J H, Beets, G L, Rutten, H J T, Kusters, M & the Lateral Node Study Consortium 2019, ' Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low ct3/4 rectal cancer ', Journal of Clinical Oncology, vol. 37, no. 1, pp. 33-43 . https://doi.org/10.1200/JCO.18.00032, Journal of Clinical Oncology, 37(1). American Society of Clinical Oncology
- Publication Year :
- 2019
-
Abstract
- Purpose Improvements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR. This multicenter pooled analysis aims to ascertain whether LLNs actually pose a problem and whether LLND results in fewer LLRs. Patients and Methods Data from 1,216 consecutive patients with cT3/T4 rectal cancers up to 8 cm from the anal verge who underwent surgery in a 5-year period were collected. LLND was performed in 142 patients (12%). MRIs were re-evaluated with a standardized protocol to assess LLN features. Results On pretreatment MRI, 703 patients (58%) had visible LLN, and 192 (16%) had a short axis of at least 7 mm. One hundred eight patients developed LR (5-year LR rate, 10.0%), of which 59 (54%) were LLRs (5-year LLR rate, 5.5%). After multivariable analyses, LLNs with a short axis of at least 7 mm resulted in a significantly higher risk of LLR (hazard ratio, 2.060; P = .045) compared with LLNs of less than 7 mm. In patients with LLNs at least 7 mm, (C)RT plus TME plus LLND resulted in a 5-year LLR of 5.7%, which was significantly lower than that in patients who underwent (C)RT plus TME (5-year LLR, 19.5%; P = .042). Conclusion LLR is still a significant problem after (C)RT plus TME in LLNs with a short axis at least 7 mm on pretreatment MRI. The addition of LLND results in a significantly lower LLR rate.
- Subjects :
- Cancer Research
medicine.medical_treatment
DISEASE
03 medical and health sciences
0302 clinical medicine
medicine
DISSECTION
Neoadjuvant therapy
RESECTION MARGIN
JAPAN
medicine.diagnostic_test
business.industry
Hazard ratio
Magnetic resonance imaging
Total mesorectal excision
Radiation therapy
Dissection
Oncology
030220 oncology & carcinogenesis
METASTASIS
Resection margin
SURVIVAL
business
Nuclear medicine
PREOPERATIVE CHEMORADIOTHERAPY
Chemoradiotherapy
030215 immunology
RADIOTHERAPY
Subjects
Details
- Language :
- English
- ISSN :
- 0732183X
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology, 37(1), 33, Journal of Clinical Oncology, 37(1), 33-43. American Society of Clinical Oncology, Ogura, A, Konishi, T, Cunningham, C, Garcia-Aguilar, J, Iversen, H, Toda, S, Lee, I K, Lee, H X, Uehara, K, Lee, P, Putter, H, van de Velde, C J H, Beets, G L, Rutten, H J T, Kusters, M & the Lateral Node Study Consortium 2019, ' Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low ct3/4 rectal cancer ', Journal of Clinical Oncology, vol. 37, no. 1, pp. 33-43 . https://doi.org/10.1200/JCO.18.00032, Journal of Clinical Oncology, 37(1). American Society of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....a31b289b70110a2d542710ab9dd6c6f9